Source: Annual Congress 2010 - Pharmacological treatment in primary care
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Price, M. Ali, A. Burden, A. Chisholm, L. Kemp, A. J. Lee, N. Roche, J. C. Virchow, J. von Zeigenweidt (Aberdeen, Norwich, United Kingdom; , France; Rostock, Germany). Device type and real-world effectiveness of combination therapy. Eur Respir J 2010; 36: Suppl. 54, 846

Member's Comments

No comment yet.

Related content which might interest you: Evaluation of efficacy and safety of budesonide/formeterol combination therapy in asthma patients Source: Eur Respir J 2006; 28: Suppl. 50, 314s Year: 2006 Comparative efficacy of the therapy strategies for the asthma control maintenance in real clinical practice Source: Annual Congress 2011 - Asthma: control and treatment Year: 2011 Impact of smart digital therapy feedback, motivation and assistance on CPAP adherence: a randomized-controlled trial Source: Virtual Congress 2020 – Digital health interventions in respiratory medicine Year: 2020 Comparison of efficacy and safety of fixed-dose combination regimen versus separate drugs for treatment of tuberculosis Source: International Congress 2019 – Insights into paediatric bronchology Year: 2019 Monitoring adherence to treatment regimen of inhaled medication use in a clinical trial with an investigational eFlow nebulizer (eTrack) Source: International Congress 2017 – Medical education, web and internet Year: 2017 Real-world effectiveness and cost-effectiveness of asthma step-up options: A UK comparison of extrafine hydrofluoroalkane-beclometasone and combination therapy Source: Annual Congress 2013 –Treatment and management of asthma in primary care Year: 2013 Eliminating in-vitro drug-drug interactions in dual and triple fixed-dose combination therapies using a novel cosuspension metered dose inhaler platform Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013 IMPACT: Healthcare resource use data and associated costs for single-inhaler triple therapy versus dual therapies in Spain Source: Virtual Congress 2021 – Difficult decisions on expected outcomes: availability of hospital resources and improvement of treatment adherence Year: 2021 Cost consequences of tiotropium plus existing therapy versus existing therapy alone following one year of treatment in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 5s Year: 2001 One-year pulmonary safety and efficacy of inhaled insulin as adjunctive therapy in type 2 diabetes patients poorly controlled on oral agent monotherapy Source: Eur Respir J 2004; 24: Suppl. 48, 618s Year: 2004 Highly efficient dual and triple combination therapies with no coformulation effect for treatment of COPD Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012 Safety and effectiveness of flexible endobronchial cryotherapy as a diagnostic and concurrently therapeutic modality Source: Annual Congress 2010 - Airway patency: the role of interventional bronchoscopy Year: 2010 Effectiveness versus efficacy trials in COPD: how study design influences outcomes and applicability Source: Eur Respir J, 51 (2) 1701531; 10.1183/13993003.01531-2017 Year: 2018 Efficacy and safety of once-daily single-inhaler triple therapy in patients with inadequately controlled asthma: the CAPTAIN trial Source: Breathe, 17 (1) 200279; 10.1183/20734735.0279-2020 Year: 2021 Macrolide combination therapy for hospitalised CAP patients? An individualised approach supported by machine learning Source: Eur Respir J, 54 (6) 1902111; 10.1183/13993003.02111-2019 Year: 2019 Dual bronchodilation vs triple therapy in the real-life DACCORD study Source: International Congress 2018 – Innovative therapies in asthma and COPD Year: 2018 Novel paradigm for inhaled therapies: simulation of drug pharmacokinetic behaviour and effect of disease Source: Eur Respir J 2003; 22: Suppl. 45, 474s Year: 2003 The IMPACT Trial: Single Inhaler Triple Therapy vs dual therapies: Consistent benefit across multiple exacerbation endpoints Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019